BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» FDA Offers Path for Contrave Approval; Orexigen Soars
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA Offers Path for Contrave Approval; Orexigen Soars
Sep. 22, 2011
By
Marie Powers
No Comments
Following a meeting with officials in the FDA's Office of New Drugs, Orexigen Therapeutics Inc. has received the green light to resolve its complete response letter for Contrave (naltrexone HCI/bupropion HCI) and resubmit the new drug application.
BioWorld